The CCL17-CCR4 Axis Is Critical for Mutant STAT6-Mediated Microenvironmental Remodeling and Therapeutic Resistance in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
CCL17-CCR4轴对于突变STAT6介导的微环境重塑和复发/难治性弥漫性大B细胞淋巴瘤的治疗耐药性至关重要。
期刊:Cancer Immunology Research
影响因子:8.2
doi:10.1158/2326-6066.CIR-25-0583
Abraham Madelyn J, Guilbert Cynthia, Gagnon Natascha, Gonçalves Christophe, Benoit Alexandre, Tran Kelly, Hiltebrand Owen, Rys Ryan N, Preston Samuel E J, Morin Ryan D, Miller Wilson H Jr, Johnson Nathalie A, Del Rincon Sonia V, Mann Koren K
淋巴瘤
细胞生物学
B细胞
TAT
CCL1
STAT6
CCL17
治疗耐药